The 2024 High-Quality Development Conference on Innovative Drugs was successfully held in Guangzhou in June. Themed ‘Innovation-Driven, Quality-Led, and Collaborative Win-Win,’ the event brought together hundreds of experts, scholars, and industry leaders from government agencies, research institutions, pharmaceutical companies, and investment firms to discuss the latest advances, policy directions, and internationalization strategies for China’s innovative drug development. The conference featured a main forum and multiple specialized sessions covering cutting-edge topics such as cell and gene therapy, AI-powered drug discovery, clinical trial optimization, and reforms in drug review and approval processes. A representative from China’s National Medical Products Administration emphasized ongoing efforts to improve the regulatory environment, accelerate market access for innovative drugs, and strengthen quality management throughout the product lifecycle—shifting the industry from quantitative expansion to qualitative advancement. As a key hub for biopharmaceutical innovation in the Greater Bay Area, Guangzhou has significantly increased policy support and infrastructure investment in recent years, fostering a robust ecosystem for innovative drug R&D. This conference not only provided a high-level platform for industry exchange but also underscored China’s firm commitment to advancing the high-quality development of its pharmaceutical sector.
2024年创新药高质量发展大会于6月在广州成功举办。本次大会以“创新驱动、质量引领、协同共赢”为主题，汇聚了来自政府、科研机构、制药企业及投资界的数百位专家学者与行业领袖，共同探讨中国创新药研发的最新进展、政策导向与国际化路径。大会设置了主论坛与多个专题分论坛，内容涵盖细胞与基因治疗、AI赋能药物研发、临床试验优化、药品审评审批制度改革等前沿议题。国家药监局相关负责人在会上强调，将持续优化监管环境，加快创新药上市步伐，同时强化全生命周期质量管理，推动产业从‘数量扩张’向‘质量提升’转型。广州作为粤港澳大湾区生物医药产业高地，近年来不断加大政策扶持与基础设施投入，已形成较为完整的创新药研发生态体系。本次大会不仅为行业搭建了高水平交流平台，也彰显了中国推动医药产业高质量发展的坚定决心。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/1470.html